New research shows that bowel cancer may set its course very early through a “Big Bang” moment when tumor cells learn to evade the immune system. Normally, immune cells detect cancer via neoantigens, abnormal proteins on the cell surface. The study found that cancer cells can silence these warning signals right from the start through epigenetic […]
Early “Big Bang” Immune Escape May Decide Bowel Cancer’s Fate Read More »
Artificial Intelligence (AI) is emerging as a powerful tool in detecting interval breast cancers—tumors that appear after a normal screening but before the next scheduled exam. These cancers are often more aggressive and harder to treat. AI helps in two key ways. First, it can reassess prior images, identifying about one-third of cancers that radiologists
AI Shows Promise in Catching Missed Breast Cancers and Predicting Future Risk Read More »
Recent research using artificial intelligence (AI) on routine low-dose CT scans suggests that body composition may help predict lung cancer risk. These scans can measure muscle, fat, and bone without extra testing. One key finding is that low muscle density (myosteatosis)—when fat infiltrates muscle tissue—strongly correlates with higher lung cancer risk. Low overall muscle mass (sarcopenia) may
AI Body Scan Analysis May Boost Lung Cancer Risk Prediction Read More »
A new study indicates that the artificial sweetener sucralose (Splenda) may reduce the effectiveness of anti-PD-1 immunotherapy in cancer by altering the gut microbiome and impairing T-cell function. In patients with melanoma and lung cancer, higher sucralose intake was linked to lower response rates and shorter progression-free survival, even after adjusting for other factors. Supporting this, mouse experiments
Common Sweetener Splenda May Weaken Cancer Immunotherapy Read More »
The phase 3 KEYNOTE-B96/ENGOT-ov65 trial (NCT05116189) showed that combining pembrolizumab (Keytruda) with weekly paclitaxel—with or without bevacizumab (Avastin)—improves survival in patients with platinum-resistant recurrent ovarian cancer (PROC). This is the first immune checkpoint inhibitor regimen to demonstrate a significant overall survival benefit in this setting. In 643 patients, the treatment improved median progression-free survival (PFS)
Pembrolizumab Combo Improves Survival in Platinum-Resistant Ovarian Cancer Read More »
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with rising cases and strong resistance to standard chemotherapy. Precision oncology is bringing new hope by identifying biomarkers and targeted treatments that can guide personalized care. Chemotherapy, including FOLFIRINOX and gemcitabine plus nab-paclitaxel, remains the main treatment, but response rates rarely exceed 40% because of
Precision Oncology Brings New Hope for Deadly Pancreatic Cancer Read More »
The Phase 3 COMPETE trial (NCT03049189) demonstrates that the radioligand therapy ¹⁷⁷Lu-edotreotide (ITM-11) offers substantial benefits for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Patients receiving ITM-11 had a median progression-free survival (PFS) of 23.9 months, compared with 14.1 months for those treated with everolimus. The therapy showed consistent benefit across both gastrointestinal and pancreatic tumors
Novel Radioligand Therapy Shows Promise for Digestive System Neuroendocrine Tumors Read More »
A new study points to the protein TRIM21 as a key driver of pancreatic adenocarcinoma (PAAD), one of the deadliest cancers with a 5-year survival rate below 9%. Using bioinformatics and lab experiments, researchers found that TRIM21 is highly overexpressed in pancreatic cancer tissues and strongly linked to poor patient outcomes. High levels of TRIM21
TRIM21 Identified as Promising New Target in Pancreatic Cancer Treatment Read More »
Researchers have developed a simple, cost-effective test to classify BRAF V600E–mutant colorectal cancer (CRC), advancing personalized therapy. The new immunohistochemistry (IHC)–based system, called iBM, uses two protein markers—CD8, indicating immune activity, and ARHGEF17, involved in cell-cycle regulation—to identify tumor subtypes without expensive genomic sequencing. The test categorizes tumors into two groups: iBM1, with high immune
Simple Two-Marker Test May Transform Treatment for BRAF-Mutant Colorectal Cancer Read More »
A recent study shows that genetic variants linked to Type 2 Diabetes (T2D) can predict poorer outcomes in metastatic colon cancer (mCC), even in patients without diabetes. Researchers analyzed 15 T2D-associated genes in 99 non-diabetic mCC patients over a median follow-up of 42 months. Two variants were particularly impactful: CDKN1B p.V109G carriers had a median
Type 2 Diabetes Genes Linked to Poor Survival in Metastatic Colon Cancer Read More »